Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Randomised controlled trial of azithromycin in smokers with asthma

Euan J. Cameron, Rekha Chaudhuri, Frances Mair, Charles McSharry, Nicola Greenlaw, Christopher J. Weir, Lisa Jolly, Iona Donnelly, Katie Gallacher, Deborah Morrison, Mark Spears, Tom J. Evans, Kenneth Anderson, Neil C. Thomson
European Respiratory Journal 2013 42: 1412-1415; DOI: 10.1183/09031936.00093913
Euan J. Cameron
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rekha Chaudhuri
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances Mair
2General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles McSharry
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Greenlaw
3Robertson Centre for Biostatistics, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Weir
3Robertson Centre for Biostatistics, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Jolly
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iona Donnelly
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie Gallacher
2General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Morrison
2General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Spears
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom J. Evans
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Anderson
4Respiratory Medicine, Crosshouse Hospital, Kilmarnock, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil C. Thomson
1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: neil.thomson@glasgow.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Smokers with asthma have poor symptom control, accelerated decline in lung function and an attenuated response to corticosteroids compared to nonsmokers with asthma [1]. There is an unmet need for alternative or additional drugs for smokers with asthma who are unable to stop smoking [2]. Macrolide antibiotics have anti-inflammatory activity [3] and in clinical studies there is good evidence for efficacy in the treatment of diffuse pan-bronchiolitis and cystic fibrosis, as well as in preventing chronic rejection after lung transplantation [4, 5]. In asthma, chronic treatment is associated with a reduction in bronchial hyperreactivity in mild-to-moderate asthma [6] and in exacerbation rates in non-eosinophilic severe asthma [7]. To date, no studies have examined the efficacy of macrolide antibiotics exclusively in current smokers with asthma.

A randomised double-blind parallel-group trial compared azithromycin, 250 mg per day, with placebo for 12 weeks. All subjects were aged 18–70 years, were current smokers (≥5 pack-years history) with chronic asthma (>1 year duration; defined by international criteria [8]) and had to be free of exacerbation and respiratory tract infection for a minimum 6-week period prior to randomisation. A baseline visit was performed following a 4-week run-in period on inhaled corticosteroid (ICS) therapy equivalent to 400 μg beclometasone ± a long-acting β2-agonist (LABA). Ethical approval was obtained and all subjects provided written informed consent. Study visits were performed at 4, 8 and 12 weeks. Clinic visit peak expiratory flow (PEF) after 12 weeks treatment was the primary outcome measure. A sample size of 68 was calculated to have an 80% power to detect a mean difference of 25 L·min−1 in change from baseline to 12 weeks in morning PEF, the primary end-point [9], assuming a standard deviation of changes of 36 L·min−1 using a two-sample t-test with a 5% two-sided significance level. Recruitment of 80 patients was planned to ensure that 68 patients completed the study. 77 subjects were randomised with 71 completing the study. Other measures of airway responsiveness PC20 (provocation concentration of methacholine causing a 20% fall in forced expiratory volume in 1 s (FEV1)), inflammation (exhaled nitric oxide fraction at 50 mL·s−1 (FeNO50)/induced sputum/blood and sputum supernatant biomarkers), symptom control (Asthma Control Questionnaire (ACQ) [10] and Leicester Cough Questionnaire (LCQ) [11]) and quality of life (Asthma Quality of Life Questionnaire (AQLQ) [10]) were assessed during the study. PEF was recorded using Piko-1 electronic peak flow meters (nSpire, Hertford, UK) and symptoms were recorded in a validated diary card [10]. Bacteriological and virological analysis of induced sputum was also undertaken. All statistical tests were two-sided and used a significance level of 5%. All data was analysed using SAS (version 9.2; SAS Institute, Cary, NC, USA). QTc was also measured at baseline and 12 weeks.

Baseline demographic data and clinical characteristics of the patients were comparable and the two groups were well balanced. Placebo versus azithromycin groups: age 42.8±9.4 years versus 46.4±8.8 years; male sex 17 (44.7%) versus 20 (51.3%); smoking history 23.6±15.8 pack-years versus 28.6±16.4 pack-years; duration of asthma 24.6±12.6 years versus 18.8±12.5 years; atopic 23 (60.1%) versus 27 (69.2%); median (interquartile range) total IgE 103 (38–291) IU·mL−1 versus 165 (48–254) IU·mL−1; use of ICS at screening 31 (81.6%) versus 35 (89.7%); equivalent beclomethasone dose at screening 709±564 μg versus 603±457 μg; use of LABA at randomisation 18 (47.4%) versus 15 (38.5%); pre-bronchodilator FEV1 81.0±16.8% predicted versus 78.3±16.4% pred; post-bronchodilator FEV1 89.0±15.1% pred versus 86.8±15.2% pred; FEV1 11.3±9.8% reversibility versus 12.3±10% reversibility; geometric mean PC20 1.06±4.10 mg·mL−1 versus 1.07±3.13 mg·mL−1.

At the final study visit (12 weeks) the change in mean morning clinic PEF (primary outcome), as compared with baseline, did not differ substantially between the azithromycin and placebo treatment groups (mean difference -10.3 (95% CI 47.1–26.4 L·min−1), p=0.58) (table 1). There was no difference in either pre- or post-albuterol FEV1 at 4, 8 or 12 weeks between the two groups (table 1). No differences were evident for PC20 (baseline to 12 week comparison) between the azithromycin or placebo groups (table 1). None of the self-reported diary card recordings (ACQ, AQLQ or LCQ score) demonstrated any significant differences between the two groups at 4, 8 or 12 weeks. Noninvasive measures of inflammation, i.e. induced sputum, sputum supernatant cytokines, peripheral blood cytokines and FeNO50, did not demonstrate any substantial improvements after 12-weeks of treatment with azithromycin (table 1). Bacterial colony counts did not demonstrate any treatment difference between the placebo and azithromycin groups (p=0.66, data not shown). PCR for Mycoplasma pneumonia and Chlamydophila pneumoniae were negative at both baseline and 12 weeks. QTc was unchanged following 12 weeks of treatment with azithromycin.

View this table:
  • View inline
  • View popup
Table 1– Clinical outcomes and sputum cell counts after azithromycin treatment or placebo

No suspected unexpected serious adverse events occurred during the reporting period of the study. Compliance assessed by capsule count was >90% in each group.

In the first randomised controlled study of azithromycin in smokers with asthma we found that there were no clinically important improvements in both the primary end-point and morning PEF, and in a range of secondary clinical outcomes including ACQ score, AQLQ score, spirometry and airway responsiveness, as well as measures of airway inflammation after 12 weeks of treatment. The median ACQ score of the participants recruited to the study was raised at 1.7 indicating that they had poorly controlled disease and scope for clinical improvement. We believe that the choice of a different macrolide from azithromycin or a different dose of azithromycin is unlikely to have altered our findings. This study was powered to test the hypothesis on the primary end-point, PEF. We exceeded our minimum recruitment target ensuring adequate numbers completed the study. The lack of response to treatment was such that recruiting greater numbers would be unlikely to affect either the primary end-point or the majority of secondary analyses. Taken together these findings indicate that short-term therapy with azithromycin does not improve lung function or other indices of current asthma control of smokers with mild-to-moderate asthma who are already receiving treatment with inhaled corticosteroids. This is supported by a recent study where 6 months of treatment with azithromycin in nonsmokers with severe asthma did not improve lung function [7].

Recently published data reported that azithromycin administered over 1 year reduced the rate of exacerbations in chronic obstructive pulmonary disease (COPD), although this benefit was not found in current smokers with COPD, and bronchiectasis was not an exclusion [12, 13]. Moreover, a 6-month study with azithromycin in nonsmokers with severe asthma powered to measure exacerbation frequency did not find any statistical difference between treatment and placebo groups [7], although a beneficial effect of azithromycin on reducing exacerbations was reported in patients with non-eosinophilic asthma [7]. The smokers with asthma in our study had non-eosinophilic asthma, but did not respond to azithromycin, although the duration of treatment was not long enough to assess the effects of azithromycin on exacerbations.

In conclusion, we have studied the effects of 12 weeks of azithromycin in smokers with asthma, an understudied patient group, and provide clear evidence demonstrating lack of efficacy in both clinical and laboratory outcomes. Further randomised clinical trials exploring new therapies in smokers with asthma who are unable to stop smoking are required.

Footnotes

  • Support statement: This work was funded by the Medical Research Council UK and supported financially by NHS Research Scotland (NRS), through the Scottish Primary Care Research Network; study medication (budesonide Easyhalers; Orion Pharma (UK), Newbury, UK) was purchased with an educational grant from AstraZeneca (London, UK).

  • Clinical trial: This study is registered at www.Clinicaltrials.gov with identifier number NCT00852579.

  • Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

  • This article was modified in April 2016 to correct errors in the licence information.

  • Received June 3, 2013.
  • Accepted July 10, 2013.
  • ©ERS 2013

ERJ Open articles are open access and distributed under the terms of the (Creative Commons Attribution Non-Commercial Licence 3.0)

References

  1. ↵
    1. Thomson N,
    2. Chaudhuri R
    . Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med 2009; 15: 39–45.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Polosa R,
    2. Thomson NC
    . Smoking and asthma: dangerous liaisons. Eur Respir J 2013; 41: 716–726.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Cameron EJ,
    2. McSharry C,
    3. Chaudhuri R,
    4. et al
    . Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy 2012; 42: 1302–1312.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Spagnolo P,
    2. Fabbri LM,
    3. Bush A
    . Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013; 42: 239–251.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Vos R,
    2. Vanaudenaerde BM,
    3. Verleden SE,
    4. et al
    . A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164–172.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Sutherland ER,
    2. King TS,
    3. Icitovic N,
    4. et al
    . A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010; 126: 747–753.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Brusselle GG,
    2. Vanderstichele C,
    3. Jordens P,
    4. et al
    . Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322–329.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA, 2010. www.ginasthma.org.
  9. ↵
    1. Greening A,
    2. Ind P,
    3. Northfield M,
    4. et al
    . Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Reddel HK,
    2. Taylor DR,
    3. Bateman ED,
    4. et al
    . An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Birring SS,
    2. Prudon B,
    3. Carr AJ,
    4. et al
    . Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339–343.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Albert RK,
    2. Connett J,
    3. Bailey WC,
    4. et al
    . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689–698.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Yamaya M,
    2. Azuma A,
    3. Takizawa H,
    4. et al
    . Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485–494.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 5 Table of Contents
European Respiratory Journal: 42 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Randomised controlled trial of azithromycin in smokers with asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Randomised controlled trial of azithromycin in smokers with asthma
Euan J. Cameron, Rekha Chaudhuri, Frances Mair, Charles McSharry, Nicola Greenlaw, Christopher J. Weir, Lisa Jolly, Iona Donnelly, Katie Gallacher, Deborah Morrison, Mark Spears, Tom J. Evans, Kenneth Anderson, Neil C. Thomson
European Respiratory Journal Nov 2013, 42 (5) 1412-1415; DOI: 10.1183/09031936.00093913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Randomised controlled trial of azithromycin in smokers with asthma
Euan J. Cameron, Rekha Chaudhuri, Frances Mair, Charles McSharry, Nicola Greenlaw, Christopher J. Weir, Lisa Jolly, Iona Donnelly, Katie Gallacher, Deborah Morrison, Mark Spears, Tom J. Evans, Kenneth Anderson, Neil C. Thomson
European Respiratory Journal Nov 2013, 42 (5) 1412-1415; DOI: 10.1183/09031936.00093913
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society